Stocks · News reference
BioCryst Announces Approval Of ORLADEYO For Pediatric HAE Patients In Japan
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BioCryst Pharma shares are trading lower after RBC Capital downgraded the stock from Outperform to Sector Perform rating and lowered its price target from $13 to $11.
RBC Capital Downgrades BioCryst Pharma to Sector Perform, Lowers Price Target to $11
RBC Capital analyst Brian Abrahams downgrades BioCryst Pharma (NASDAQ:BCRX) from Outperform to Sector Perform and lowers the price target from $13 to $11.
Needham Reiterates Buy on BioCryst Pharma, Maintains $16 Price Target